comparemela.com

Latest Breaking News On - Biocryst pharmaceuticals inc - Page 1 : comparemela.com

Oracle Investment Management Inc Sells 19,964 Shares of BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX)

Oracle Investment Management Inc. reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 3.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 535,558 shares of the biotechnology company’s stock after selling 19,964 shares during the period. […]

Avoro Capital Advisors LLC Increases Position in BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX)

Avoro Capital Advisors LLC lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 13.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,050,000 shares of the biotechnology company’s stock after purchasing an additional 1,500,000 shares during […]

Avoro Capital Advisors LLC Increases Position in BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX)

Avoro Capital Advisors LLC lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 13.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,050,000 shares of the biotechnology company’s stock after purchasing an additional 1,500,000 shares during […]

Analysts Set BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Price Target at $14 00

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has received a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued a report on the stock in the last […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.